HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Preprints, Working Papers, ...

Development of an in-house Quantitative ELISA for the Evaluation of Different Covid-19 Vaccines in Human

Abstract : Purpose: Reliable serological assays are needed to understand the real impact of COVID-19. In order to compare the e ciency of different COVID-19 vaccines used in the National Vaccination Program in Tunisia, we have developed a quantitative in-house ELISA. Methods: The ELISA is based on the ectodomain of the SARS-CoV-2 Spike Baculovirus recombinant protein. We have used a panel of 145 COVID-19 RT-PCR positive serum samples and 116 pre-pandemic serum samples as a negative panel. The validation was carried out by comparison to four commercial techniques (Vidas® SARS-CoV-2 IgG anti-RBD Biomérieux®, Elecsys® Anti-Nucleocapsid of SARS-CoV-2 Roche®, cPass® GenScript® and the quantitative Elecsys® Anti-RBD of SARS-CoV-2, Roche®). For the evaluation of the National Vaccination campaign, we have included 115 recipients of one of the different used vaccines. Results: The qualitative performances of the developed ELISA gave 96% sensitivity, 97.5% speci city and 0.968 accuracy. For the evaluation of the different brand of vaccines in recipients not previously infected with SARS-CoV-2, it seems that mRNA vaccine of P zer/BioNTech has shown a higher e cacy compared to inactivated virus vaccines. COVID-19 convalescent individuals have generated poor antibody responses. Nevertheless, when they are vaccinated with any brand of the COVID-19 vaccines, many of them mounted an exponential increase of the induced immune responses, quali ed as a "hybrid vigor immunity". Conclusion: Our developed in-house ELISA seems to be very e cient in evaluating the effectiveness of anti-COVID-19 vaccination. Platforms based on mRNA vaccine are better performing than that based on inactivated virus.
Document type :
Preprints, Working Papers, ...
Complete list of metadata

https://hal-riip.archives-ouvertes.fr/pasteur-03542087
Contributor : Abdelhakim Ben Hassine Connect in order to contact the contributor
Submitted on : Tuesday, January 25, 2022 - 10:26:16 AM
Last modification on : Tuesday, January 25, 2022 - 10:48:36 AM
Long-term archiving on: : Tuesday, April 26, 2022 - 6:53:04 PM

File

bbnn.pdf
Files produced by the author(s)

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Collections

Citation

Mariem Gdoura, Fatma Ghaloum, Meriem Hamida, Wafa Chamsa, Henda Triki, et al.. Development of an in-house Quantitative ELISA for the Evaluation of Different Covid-19 Vaccines in Human. 2022. ⟨pasteur-03542087⟩

Share

Metrics

Record views

126

Files downloads

11